Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
01 Novembro 2024 - 5:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2024
Commission File Number 001-42300
Baird Medical Investment Holdings
Limited
Room 202, 2/F, Baide Building, Building 11,
No.15
Rongtong Street, Yuexiu District, Guangzhou,
Peoples Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x Form 40-F ¨
Explanatory Note
This current report on Form 6-K is furnished
in connection with the resignation of Mr. Kun Seng Ng from the position of the chief financial officer and company secretary
of Baird Medical Investment Holdings Limited (the “Company”) for personal reasons, which did not result from any disagreement
with the Company on any matters relating to the Company’s operations, policies or practice. Ms. Jie Li will serve as the acting
chief financial officer of the Company following Mr. Kun Seng Ng’s resignation, effective from November 1, 2024.
Ms. Jie Li has served as the Company’s
reporting director since May 2024. Prior to joining the Company, Ms. Li gained extensive experience from “Big Four”
PRC-based accounting firms from 2010 to 2017 and had served as an audit manager since 2015. After that, Ms Li had more than five-year
working experience in U.S. listed companies where she was in charge of the public companies’ overall financial reporting and internal
control over financial reporting. Ms. Li received a bachelor’s degree in management accounting from Capital University of Economics
and Business in 2010. Ms. Li has been a member of the Chinese Institute of Certified Public Accountants since 2019 and obtained the
qualification of Association of Chartered Certified Accountants in 2015.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
By: |
/s/ Haimei Wu |
|
Name: Haimei Wu |
|
Title: Chairwoman and Chief Executive Officer |
Baird Medical Investment (NASDAQ:BDMDW)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Baird Medical Investment (NASDAQ:BDMDW)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024